In June 2017 the International Motorcycling Federation (FIM) has reported an anti-doping rule violation against the America rider Cade Clason after his sample tested positive for the prohibited substances Amfetamine and Dexamphetamine (d-amphetamine, dextroamphetamine). After notification a provisional suspension was ordered.
The Athlete demonstrated with medical information that he suffered from Attention Deficit Hyperactivity Disorder (ADHD) and used prescribed Adderall medication as treatment. Previously in March 2015 the FIM TUE Board had denied the Athlete’s TUE application for the use of Adderall because of the lack of relevant and supporting evidence. Hereafter in March 2019 the FIM TUE Board granted the Athlete a TUE for Adderall after it had received sufficient medical evidence of his practitioners. However WADA did not agree that the Athlete was permitted to apply for a retroactive TUE.
FIM accepts that the violation was not intentional and caused by using Adderall medication as treatment for the Athlete’s ADHD problems. FIM considers that meanwhile a TUE application for the use of Amfetamine was granted in March 2019 but that the Athlete failed to mention his medication on the Doping Control Form.
The parties in this case reached a settlement agreement and accordingly on 21 june 2019 a 2 year period of ineligibility was imposed on the Athlete starting on the date of the provisional suspension, i.e. on 21 June 2017.
